Desonide

Generic Name: Desonide

Brand Names: Desonate, Desowen, Desrx, Lokara, Tridesilon, Verdeso

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₂O_₆

CAS Number: 638-94-8

Unique Ingredient Identifier: J280872D1O

Background: A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.

Indication: For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.

Associated Conditions: Dermatosis, Ocular Inflammation, Mild Atopic dermatitis, Moderate Atopic dermatitis

Clinical Trials

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

Phase 1

Completed

Conditions: Vasoconstriction

Interventions: Drug: Clobetasol Propionate 0.05% Lotion
Drug: Desonide 0.05% Cream
Drug: MC2-01 Cream
Drug: Betamethasone Dipropionate 0.05% Cream
Drug: Triamcinolone Acetonide 0.1% Cream
Drug: Vehicle
Drug: Hydrocortisone Butyrate 0.1% Cream

First Posted Date: 2018-11-29

Last Posted Date: 2020-01-09

Lead Sponsor: MC2 Therapeutics

Target Recruit Count: 36

Registration Number: NCT03758365

Locations: 🇫🇷
CPCAD, Nice, France

Alternation in the Human Microbiome With Commonly Used Topical Medications

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Desonide 0.05%
Drug: Ketoconazole 2%

First Posted Date: 2018-02-19

Last Posted Date: 2025-02-07

Lead Sponsor: University of California, Davis

Target Recruit Count: 24

Registration Number: NCT03437005

Locations: 🇺🇸
University of California, Davis, Department of Dermatology, Sacramento, California, United States

8-Week Atopic Dermatitis (AD) Treatment Study

Phase 3

Completed

Conditions: Atopic Dermatitis Eczema

Interventions: Drug: Investigational OTC Cream
Other: Placebo Cream
Drug: 0.05% Desonide

First Posted Date: 2017-12-29

Last Posted Date: 2020-12-17

Lead Sponsor: Procter and Gamble

Target Recruit Count: 65

Registration Number: NCT03386032

Locations: 🇺🇸
WR (Wake Research) ClinSearch, Chattanooga, Tennessee, United States
🇺🇸
Wake Research, LLC, Raleigh, North Carolina, United States

Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

Phase 4

Completed

Conditions: Dermatitis, Atopic
Eczema

Interventions: Other: Cosmetic Eczema Cream
Drug: Investigational OTC Cream
Other: Placebo Cream
Drug: 0.05% Desonide Cream

First Posted Date: 2016-04-08

Last Posted Date: 2016-10-05

Lead Sponsor: Procter & Gamble Beauty

Target Recruit Count: 53

Registration Number: NCT02732314

Locations: 🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States

Proton Pump Inhibitors Use in Patients With Psoriasis

Phase 4

Withdrawn

Conditions: Psoriasis

Interventions: Drug: esomeprazole
Drug: desonide

First Posted Date: 2015-12-08

Last Posted Date: 2022-08-05

Lead Sponsor: EMS

Registration Number: NCT02624544

Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis

Phase 3

Conditions: Dermatitis, Atopic
Eczema

Interventions: Drug: Desonide Cream
Other: Amino Acid Moisturizing Cream

First Posted Date: 2014-11-10

Last Posted Date: 2014-11-11

Lead Sponsor: NeoStrata Company, Inc.

Target Recruit Count: 42

Registration Number: NCT02286700

Locations: 🇺🇸
Mass General Hospital: Clinical Unit for Research Trials in Skin, Boston, Massachusetts, United States

Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation

Phase 4

Completed

Conditions: Hyperpigmentation

Interventions: Drug: Niacinamide
Drug: Placebo
Drug: Desonide

First Posted Date: 2012-03-02

Last Posted Date: 2012-11-29

Lead Sponsor: Universidad Autonoma de San Luis Potosí

Target Recruit Count: 28

Registration Number: NCT01542138

Locations: 🇲🇽
Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosi, Mexico

Efficacy Emollient on Xerosis in Children With Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: V0034CR01B
Drug: Vehicle cream
Drug: desonide 0.1% cream
Other: Foaming gel

First Posted Date: 2011-11-08

Last Posted Date: 2013-02-21

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 251

Registration Number: NCT01467362

Locations: 🇱🇹
Lithuania, Vilnius, Lithuania
🇵🇱
Poland, Żyrardów, Poland
🇪🇪
Estonia, Tartu, Estonia

and more 2 locations

Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Device: EpiCeram Skin Barrier Emulsion
Drug: Desonide Cream 0.05%

First Posted Date: 2009-01-26

Last Posted Date: 2017-01-30

Lead Sponsor: Promius Pharma, LLC

Target Recruit Count: 100

Registration Number: NCT00828412

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston Salem, North Carolina, United States
🇺🇸
Dermatology Research Associates, Cincinnati, Ohio, United States
🇺🇸
University of Texas, Houston, Texas, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy